Surgery Versus Radiation Treatment for High-Grade Neuroendocrine Cancer of Uterine Cervix: A Surveillance Epidemiology and End Results Database Analysis

Hou, Wen Hsuan; Schultheiss, T.E.; Wong, Jeffrey Y.C.; Wakabayashi, Mark T.; Chen, Yi Jen

doi:10.1097/igc.0000000000001143

Cited by 19 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhou et al 5 who analyzed data of 208 patients with stage I-II SCNEC found that age was an independent prognostic factor for OS (HR = 1.017, P = .004). Similarly, Hou et al 14 found a significant OS benefit in younger cases (P = .005) with high-grade neuroendocrine carcinoma in a retrospective analysis.…”

Section: Survivalmentioning

confidence: 73%

“…Several reports have also found a worse survival outcomes with increasing age. 5,7,14 In a retrospective study of 130 patients with SCNEC, age older than 60 years was proved to be an independent prognostic factors for CSS regardless of stage. 7 Among the patients with IIB-IVB stage, those aged younger than 45 years had significantly lower risk of cancer death than those aged 45 to 60 years (HR, 3.4; P = .035).…”

Section: Survivalmentioning

confidence: 99%

“…The more advanced stages were found to be correlated with worse survival in several studies. [13][14][15][16][17][18][19] Zhang et al 15 showed that the median survival time (MST) of SCNEC patients with early-stage (I-IIA) was longer than those with advanced-stage (IIB-IV) (60 vs 30 months, P = .016). However, the FIGO stage was not an independent prognostic factor in the multivariate analyses.…”

Section: Survivalmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic factors and treatment comparison in small cell neuroendocrine carcinoma of the uterine cervix based on population analyses

Lin

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Objective We aimed to assess the impact of the treatment modality on the outcome of small cell neuroendocrine cervical carcinoma (SCNEC) using the Surveillance Epidemiology and End Results (SEER) database. Methods Patients from the SEER program between 1981 and 2014 were identified. Significant factors for cancer‐specific survival (CSS) and overall survival (OS) were analyzed using the Kaplan‐Meier survival and Cox regression methods. Results A total of 503 SCNEC patients were identified. The 5‐year CSS and OS were 36.6% and 30.6%, respectively. The International Federation of Gynecology and Obstetrics (FIGO) stage I to IV distributions was 189 (37.6%), 108 (21.5%), 95 (18.9%), and 111 patients (22.0%), respectively. Within the patients with known treatment strategies, 177 (45.9%) were treated with radical surgery and 209 (54.1%) underwent primary radiotherapy. Local treatment strategies were independent prognostic factor for CSS and OS. The 5‐year CSS for radical surgery and primary radiotherapy was 50.0% and 27.9%, respectively (P < .001). The 5‐year OS for those who received radical surgery and primary radiotherapy was 57.8%, and 29.6%, respectively (P < .001). In FIGO stage I SCNEC, patients treated with radical surgery had superior CSS (P = .001) and OS (P = .003) than those with primary radiotherapy. However, in FIGO stage II and III SCNEC, there were no differences in CSS and OS with respect to different local treatment strategies. Our results also found that the addition of brachytherapy impacted OS in the FIGO stage III SENCE (P = .002). The 5‐year CSS and OS of patients with FIGO IV were only 11.7% and 7.1%, respectively. Conclusions SCNEC is a rare disease with aggressive clinical behavior. The findings indicate that radical surgery should be suggested for early‐stage SCNEC and combining radiation therapy with brachytherapy should be suitable for patients with advanced stage.

show abstract

Section: Survivalmentioning

confidence: 73%

Section: Survivalmentioning

confidence: 99%

Section: Survivalmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic factors and treatment comparison in small cell neuroendocrine carcinoma of the uterine cervix based on population analyses

Lin

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Imaging and histological findings that have recently been added in the FIGO staging system are lymph node metastases. Other factors of importance include, e.g., minimum thickness of uninvolved cervical stroma, lymphovascular space invasion (LVSI), age, comorbidities (e.g., anemia, HIV infection), and high-risk histological subtypes, e.g., adenosquamous and neuroendocrine carcinomas [29–32].…”

Section: Prognosis and Treatment In Relation To Figo Stagementioning

confidence: 99%

What Is the Role of Imaging at Primary Diagnostic Work-Up in Uterine Cervical Cancer?

et al. 2019

View full text Add to dashboard Cite

Purpose of Review For uterine cervical cancer, the recently revised International Federation of Gynecology and Obstetrics (FIGO) staging system (2018) incorporates imaging and pathology assessments in its staging. In this review we summarize the reported staging performances of conventional and novel imaging methods and provide an overview of promising novel imaging methods relevant for cervical cancer patient care. Recent Findings Diagnostic imaging during the primary diagnostic work-up is recommended to better assess tumor extent and metastatic disease and is now reflected in the 2018 FIGO stages 3C1 and 3C2 (positive pelvic and/or paraaortic lymph nodes). For pretreatment local staging, imaging by transvaginal or transrectal ultrasound (TVS, TRS) and/or magnetic resonance imaging (MRI) is instrumental to define pelvic tumor extent, including a more accurate assessment of tumor size, stromal invasion depth, and parametrial invasion. In locally advanced cervical cancer, positron emission tomography-computed tomography (PET-CT) or computed tomography (CT) is recommended, since the identification of metastatic lymph nodes and distant metastases has therapeutic consequences. Furthermore, novel imaging techniques offer visualization of microstructural and functional tumor characteristics, reportedly linked to clinical phenotype, thus with a potential for further improving risk stratification and individualization of treatment. Summary Diagnostic imaging by MRI/TVS/TRS and PET-CT/CT is instrumental for pretreatment staging in uterine cervical cancer and guides optimal treatment strategy. Novel imaging techniques may also provide functional biomarkers with potential relevance for developing more targeted treatment strategies in cervical cancer.

show abstract

“…Our data showed that surgery and radiotherapy were associated with improved survival, but they failed to be prognostic predictors in multivariate analysis. Another prior SEER database analysis revealed that radical surgery and primary radiation yielded equally poor survival (5year OS rates were: 25% vs. 32%, p = 0.636) [26]. In China, radical hysterectomy-based surgery followed by adjuvant therapy is the primary treatment for patients with NECC in early FIGO stages [27].…”

Section: Discussionmentioning

confidence: 99%

Construction and Validation of the Prognostic Model for Patients With Neuroendocrine Cervical Carcinoma: A Competing Risk Nomogram Analysis

Jiang¹,

Cai²

2020

Preprint

View full text Add to dashboard Cite

Purpose: Neuroendocrine cervical carcinoma (NECC) is an uncommon malignancy of the female reproductive system. This study aimed to evaluate the cancer-specific mortality and to construct prognostic nomograms for predicting the survival of patients with NECC.Methods: we assembled the patients with NECC diagnosed between 2004 to 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. Meanwhile, we identified other patients with NECC from the Wenling Maternal and Child Health Care Hospital between 2002 to 2017. Fine and Gray’s test and Kaplan-Meier methods were used to evaluate cancer-specific mortality and overall survival (OS) rates, respectively. Nomograms were constructed for predicting cancer-specific survival (CSS) and OS for patients with NECC. The developed nomograms were validated both internally and externally.Results: a total of 894 patients with NECC extracted from the SEER database, then classified them into the training cohort (n=628) and the internal validation cohort (n=266). Besides, 106 patients from the Wenling Maternal and Child Health Care Hospital served as an external validation cohort. Nomograms for predicting CSS and OS were constructed on clinical predictors. The validation of nomograms was calculated by calibration curves and concordance indexes (C-indexes). Furthermore, the developed nomograms presented higher areas under the receiver operating characteristic (ROC) curves when compared to the FIGO staging system.Conclusions: we established the first competing risk nomograms to predict the survival of patients with NECC. Such a model with excellent performance could be a practical tool for clinicians.

show abstract

Surgery Versus Radiation Treatment for High-Grade Neuroendocrine Cancer of Uterine Cervix: A Surveillance Epidemiology and End Results Database Analysis

Abstract: Patients with cervical HGNECs had poor prognosis. Primary treatment by radical surgery or external beam radiotherapy with or without brachytherapy yielded equally poor survival.

Cited by 19 publications

References 28 publications

Prognostic factors and treatment comparison in small cell neuroendocrine carcinoma of the uterine cervix based on population analyses

Prognostic factors and treatment comparison in small cell neuroendocrine carcinoma of the uterine cervix based on population analyses

What Is the Role of Imaging at Primary Diagnostic Work-Up in Uterine Cervical Cancer?

Construction and Validation of the Prognostic Model for Patients With Neuroendocrine Cervical Carcinoma: A Competing Risk Nomogram Analysis

Contact Info

Product

Resources

About